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CONTEMPORARY REVIEW
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Prevention and Treatment of Cardiovascular 
Disease Among Young Adults: Report From 
a National Heart, Lung, and Blood Institute 
Working Group
Holly C. Gooding , MD, MSc; Samuel S. Gidding , MD; Andrew E. Moran , MD, MPH;  
Nicole Redmond , MD, PhD, MPH; Norrina B. Allen , PhD, MPH; Fida Bacha , MD; Trudy L. Burns, PhD, MPH; 
Janet M. Catov , PhD, MS; Michael A. Grandner , PhD, MTR; Kathleen Mullan Harris , PhD;  
Heather M. Johnson , MD, MS; Michaela Kiernan, PhD; Tené T. Lewis , PhD; Karen A. Matthews, PhD; 
Maureen Monaghan, PhD; Jennifer G. Robinson, MD, MPH; Deborah Tate, PhD;  
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ABSTRACT: Improvements in cardiovascular disease (CVD) rates among young adults in the past 2 decades have been offset 
by increasing racial/ethnic and gender disparities, persistence of unhealthy lifestyle habits, overweight and obesity, and other 
CVD risk factors. To enhance the promotion of cardiovascular health among young adults 18 to 39 years old, the medical 
and broader public health community must understand the biological, interpersonal, and behavioral features of this life stage. 
Therefore, the National Heart, Lung, and Blood Institute, with support from the Office of Behavioral and Social Science 
Research, convened a 2-day workshop in Bethesda, Maryland, in September 2017 to identify research challenges and op-
portunities related to the cardiovascular health of young adults. The current generation of young adults live in an environment 
undergoing substantial economic, social, and technological transformations, differentiating them from prior research cohorts 
of young adults. Although the accumulation of clinical and behavioral risk factors for CVD begins early in life, and research 
suggests early risk is an important determinant of future events, few trials have studied prevention and treatment of CVD in 
participants <40 years old. Building an evidence base for CVD prevention in this population will require the engagement of 
young adults, who are often disconnected from the healthcare system and may not prioritize long-term health. These changes 
demand a repositioning of existing evidence-based treatments to accommodate new sociotechnical contexts. In this article, 
the authors review the recent literature and current research opportunities to advance the cardiovascular health of today’s 
young adults.
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Despite an overall population-wide decline in car-diovascular disease (CVD) mortality in the United States since 1968,1 detailed analysis of age-spe-
cific rates reveals concerning trends within young adult 
populations. For example, the proportion of acute 
myocardial infarctions attributable to patients <55 
years old has increased from 27% to 32% in the past 
20 years.2 and among women 35 to 44 years old, the 
mortality rate from CVD has increased ≈1.3% per year 
(95% CI, 0.2–2.5) since 1997.3 Acute ischemic stroke 
hospitalizations have also increased significantly for 
men and women 18 to 44 years old, with men 35 to 
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44 years old demonstrating a doubling of acute isch-
emic stroke hospitalizations since 1996.4 Although im-
provements have been made in acute cardiovascular 
care, these gains have been offset by increasing racial/
ethnic and gender disparities, persistence of unhealthy 
lifestyle habits, overweight and obesity, and other 
CVD risk factors such as diabetes mellitus (DM) and 
hypertension.2,4–7
To enhance efforts promoting the cardiovascular 
health (CVH) of young adults, defined as 18 to 39 years 
old, the medical and broader public health community 
should understand the unique confluence of biological, 
interpersonal, and behavioral features of this life stage. 
The current generation of 21st century young adults 
live in an environment undergoing substantial eco-
nomic, social, and technological transformations, dif-
ferentiating them from young adults just 10 or 20 years 
ago. These changes demand a refashioning of existing 
evidence-based treatments to accommodate new so-
ciotechnical contexts. Building an evidence base for 
CVD prevention in this population will require engage-
ment of young adults, who are often disconnected 
from the healthcare system and may be unmotivated 
or unable to prioritize their long-term health. Although 
the accumulation of clinical and behavioral risk factors 
for CVD begins early in the life course, few trials have 
studied prevention and treatment of CVD in partici-
pants <40 years old.
The National Heart, Lung, and Blood Institute 
(NHLBI), with support from the Office of Behavioral 
and Social Science Research, convened a 2-day 
workshop in Bethesda, Maryland, in September 
2017 to identify research challenges and opportuni-
ties related to the CVH of young adults. Further de-
tails of the meeting and deliberations of the working 
group can be found on the NHLBI website.8 A smaller 
writing group comprised of 5 members of the work-
ing group later convened to develop 2 conceptual 
frameworks summarizing the presentations of the 
independent experts. The first framework (Figure 1), 
inspired by the socioecological model9 and the 
pathways linking socioeconomic status (SES) and 
health model,10 conceptualizes the CVH of young 
adults as influenced by individual, demographic, and 
community factors situated within a contemporary 
context. The second framework (Figure 2), inspired 
by the Life Course Health Development Framework,11 
posits how these various influences create enduring 
vulnerabilities that influence the trajectory of CVH 
during and after young adulthood. The writing group 
then worked with NHLBI staff and each member of 
the working group to update the recent literature in 
their respective domains. Consistent with the original 
goals of the workshop and funding priorities of the 
NHLBI, in this article we focus primarily on athero-
sclerotic coronary heart disease (CHD) and its risk 
factors, although related health conditions such as 
DM and stroke are discussed where relevant. We re-
view the recent literature and conclude with sugges-
tions for research to address the unique CVH needs 
of today’s young adults.
CVH OF YOUNG ADULTS
Young adulthood encompasses the age range be-
tween 18 and 39 years old.12 During this period, young 
adults may complete their education, enter the work-
force, establish social networks and romantic relation-
ships, create a family, and set financial goals.13 Critical 
health behaviors are either established or lost, help-
ing to shape a life-long trajectory of CVH and well-
being.14,15 Importantly, young adults often become 
parents, thereby initiating intergenerational CVH pat-
terns and exposures.
In 2010, the American Heart Association set the 
bold goal of improving CVH of all Americans by 20% 
by 2020.16 To assess CVH, it chose 4 lifestyle factors 
(nonsmoking status, healthy diet, physical activity pat-
terns, and healthy weight) and 3 clinical factors (optimal 
blood pressure, blood glucose, and blood lipid levels) 
consistently shown in epidemiologic studies to be asso-
ciated with living longer, healthier lives. For the 7 metrics 
(with the exception of diet) and for the CVH construct 
overall, children and adolescents are much more likely 
to have ideal levels than adults. The “Heart Disease and 
Stroke Statistics—2020 Update” from the American 
Heart Association addresses these trends (see Figure 3 
excerpted from the update) based on data from the 
National Health and Nutrition Examination Survey.17
The transition from the relatively ideal CVH of 
children to the poor CVH of older adults occurs in 
young adulthood. Considerably fewer young adults 
(35.2%) meet the criteria for ideal body mass index 
(BMI) compared with adolescents (60.1%). Young 
adults are also less likely than adolescents to meet 
ideal levels of total cholesterol, blood pressure, and 
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fasting glucose (Figure  3). Importantly, in both chil-
dren and adults, the proportion of the US population 
meeting ideal criteria for blood pressure and total 
cholesterol has risen over the past decade, while the 
prevalence of ideal BMI and glucose levels has de-
clined.17 There is robust evidence that type 2 DM is 
increasing in younger individuals worldwide as well.18 
Although use of traditional cigarettes has declined for 
young adults, they are increasingly using e-cigarette 
products that appear to pose cardiovascular risk.19–21 
E-cigarette use by young adults is also associated 
with subsequent adoption of traditional tobacco 
products22 thus, this may portend a worsening of the 
smoking metric in future years.
Although not 1 of the original 7 ideal CVH met-
rics, sleep health is also critical to CVH and is in-
sufficient among young adults, with 38% reporting 
an inadequate sleep duration (<7 hours per night).23 
Adolescents with inadequate sleep are more likely 
to be obese and have elevated glucose and insulin 
levels, higher blood pressure, greater fat mass, and 
more behavioral risk factors such as physical inactiv-
ity and an unhealthy diet.24,25 Adults with inadequate 
sleep duration are more likely to be obese and phys-
ically inactive, report substance use including use of 
tobacco products, experience depressed mood and 
anxiety symptoms, and develop chronic diseases 
such as hypertension and DM.23,26
Figure 1. Multilevel influences on young adult cardiovascular health.
The multilevel factors influencing young adult cardiovascular health are depicted here as concentric circles including individual, 
interpersonal, and community factors situated within a contemporary context referred to as cohort effects. Similar to the socioecological 
model,7 this framework supposes that outer rings influence the rings within them. Similar to the pathways linking SES and health 
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MULTILEVEL INFLUENCES ON THE 
CVH OF YOUNG ADULTS
As depicted in Figures 1 and 2, many factors influ-
ence the CVH trajectory of young adults by contrib-
uting to either the slowing or the acceleration of the 
development of CVD. A selection of these factors is 
presented below, beginning with those unique to in-
dividuals, followed by interpersonal and community 
factors, and cohort effects. Similar to the socioeco-
logical model,7 this framework supposes that outer 
levels influence the levels within them. Similar to the 
pathways linking SES and health model,8 there are 
bidirectional relationships and interactions among 
many of the factors.
Genetic Factors
Genetic conditions cause premature heart disease, 
including familial hypercholesterolemia (prevalence 
1:250). Emerging data suggest the addition of a ge-
netic risk score to conventional risk factors may im-
prove the prediction of accelerated subclinical 
atherosclerosis in younger adults and premature onset 
of CHD events.27–31 For example, a 182-variant poly-
genic risk score predicted a 2-fold increase in risk of 
premature coronary artery disease (≤40 years old for 
men and ≤45 years old for women), a rate similar to 
that observed in individuals with heterozygous familial 
hypercholesterolemia.28
Gender
The young adult years hold important CVD preven-
tion implications for women. CVD remains the lead-
ing cause of mortality among women in the United 
States and developed countries.32 Women experi-
ence a higher fatality rate following a first myocardial 
infarction, and despite an overall decline in the CVD 
death rate in the United States, the rate of decline has 
been slower for women compared with men. In ad-
dition, the death rate is 70% higher in Black women 
compared with White women.33 Two-thirds of CHD 
sudden deaths occur in women with no previous 
symptoms compared with half of CHD sudden deaths 
in men. It is now evident that this excess mortality 
Figure 2. Causes of variation in trajectories of cardiovascular health.
The 3 cases illustrated in the figure vary from having a low early vulnerability burden that allows CVH to develop maximally (green 
curve) to having a high vulnerability burden that constrains the development of CVH (red curve). The case illustrated by the green curve 
shows high resilience to the young adult period of risk (ie, maintaining the high starting level of CVH until late in life). Both the yellow 
and the red curves show loss of CVH during the young adult risk period, illustrating a lack of resilience to the challenges imposed by 
this life period. Both the green and the yellow curves illustrate a steep slope, where CVH is lost rapidly. The comparison of the green 
and yellow curves illustrates that the clinical impact of such a rapid loss of CVH varies depending upon its timing in the life course. 
These 3 simplified curves are shown for illustrative purposes; dynamic changes to CVH trajectories across the life course are likely 
caused by alterations in the enduring vulnerabilities and risk behaviors through changes in life circumstances, individual, or public 
health interventions. CAC indicates coronary artery calcium; CHF, congestive heart failure; CIMT, carotid intima media thickness; CVA, 
cerebral vascular accident; CVD, cardiovascular disease; CVH, cardiovascular health; HTN, hypertension; MI, myocardial infarction; 
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is based in part on the increased death rate among 
premenopausal women, although less is known re-
garding coronary artery disease among this group.34 
Recent data on 20-year trends in acute myocardial 
infarction demonstrate that the proportion attributa-
ble to patients >55 years old has increased from 27% 
to 32%, with the largest increases observed in young 
women.2 Additionally, women 18 to 44 years old have 
a higher incidence rate of ischemic and nonischemic 
stroke compared with men of the same age.35 Thus, 
the detection of elevated risk in young women and a 
greater understanding of gender-related differences 
may provide a critical opportunity to delay or prevent 
onset of CVD in women.
Pregnancy
More than 80% of American women bear a child dur-
ing their young adult years36; pregnancy can be viewed 
as a “stress test,” with adverse pregnancy outcomes 
associated with increased future CVD. Hypertensive 
disorders of pregnancy (eg, preeclampsia, gestational 
hypertension) affect up to 7% of births. A firmly es-
tablished link exists between the development of hy-
pertension during pregnancy and a 2- to 8-fold higher 
risk of hypertension, CVD, and renal disease later in 
life.37 Rates of chronic hypertension 2 to 5 years after 
affected pregnancies are as high as 50% following 
early-onset preeclampsia, 39% after gestational hy-
pertension, and 25% following late-onset preeclamp-
sia.38 By comparison, hypertension rates in women 
with normotensive, term births are very low (3.8%) 
2 to 7  years after delivery.39 Diastolic dysfunction 
and asymptomatic heart failure have been detected 
4 years postpregnancy in 25% of women with preec-
lampsia.40 Women with preeclampsia have a higher 
risk of CVD within 5  years after delivery, suggesting 
that the short- and long-term cardiovascular sequelae 
are high.41,42 Thrombotic events are more likely in the 
period immediately following pregnancy.43
Gestational DM, which affects up to 10% of preg-
nancies, is associated with a 50% to 85% higher 
CVD risk in women.42,44–46 Nearly half of women who 
experience gestational DM will develop type 2 DM 
within 10 years after pregnancy.47,48 Gestational DM is 
also related to risk of atherosclerosis, even in women 
who do not progress to DM.49 Lactation may miti-
gate some of these adverse maternal consequences 
of gestational DM, suggesting that the reproductive 
years also present opportunities for risk reduction.50 
Other complications such as preterm birth are also 
linked to CVD risk.51–54 Further, there is an alarming 
increase in severe maternal morbidity and mortality 
in the United States, the dominant cause of which 
Figure 3. Prevalence of adolescents (ages 12–19 years), young adults (ages 20–39 years), and middle-aged adults (ages 
40–59 years) meeting ideal status for each of the 7 cardiovascular health metrics.
Prevalence (unadjusted) estimates of US adults across 3 age strata meeting ideal status for each of the 7 metrics of cardiovascular 
health as reported in “Heart Disease and Stroke Statistics—2020 Update” from the American Heart Association.17 BMI indicates 
body mass index; and CVH, cardiovascular health. *Healthy diet score reflects 2013 to 2014 NHANES (National Health and Nutrition 
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is cardiovascular in nature.55 There are also pro-
found racial disparities, with Black women carrying 
the highest risk for these severe events compared 
with White women.56 Evidence-based strategies to 
increase CVD risk evaluation during preconception, 
prenatal, and postnatal care are needed, as are inter-
ventions to mitigate CVD risk during this critical time 
for young adult women.
Psychological Factors
Psychological stressors are associated with CVD risk 
behaviors and CVD.57 Acute mental stress is associated 
with alterations in myocardial blood flow, and chronic 
exposure to stress is associated with alterations in 
inflammation signaling pathways.58,59 Young adults 
commonly face a variety of psychological stressors, 
including neighborhood factors and sequelae of ad-
verse childhood experiences, as well as financial hard-
ships, relationship changes, and discrimination based 
on race, gender, sexual orientation, or other societally 
disadvantaged situations. The cumulative effects of an 
increasing number of stressors, as well as the protec-
tive effects of individual and collective resilience fac-
tors, are active areas of investigation.
Three-fourths of mental health disorders are pres-
ent by 24 years old.60 Compelling evidence suggests 
that major depression and depressive symptoms pre-
dict premature heart disease morbidity and mortality. 
Putative mechanisms include standard biological and 
lifestyle factors, inflammation, oxidative stress, and 
endothelial dysfunction.61 An analysis of data from 
the National Survey on Drug Use and Health for the 
years 2005 to 2015 found an increasing prevalence 
of depression in the United States, with adolescents 
and young adults showing the largest increases, to 
13% and 10%, respectively.62 A substantial decline in 
CVH among young adults may be caused by mental 
health disorders and related obesity, physical inactivity, 
smoking, and disturbed sleep,61 although this remains 
an area for investigation.
Adverse Childhood Experiences
Adverse early life experiences may be particularly dam-
aging to CVH in young adults. Typically, these include 
physical and sexual abuse, neglect, a family member 
with mental health problems, incarceration of a parent, 
and sometimes poverty. In a sample of 29 229 adult 
men and women, more than 50% reported at least 1 
form of childhood adversity; 17% reported 4 or more 
adverse experiences.63 Not only do adverse early life 
experiences predict depression, but they are also re-
lated to behavioral and physiologic cardiovascular risk 
factors.64–67 The accumulation of adverse early life ex-
periences is predictive of clinical CVD in adulthood.68 
A meta-analysis of 9 studies (15 effects) that reported 
hazard ratios (HRs) and 29 studies that reported odds 
ratios (ORs; 62 effects) found significant associations 
between cumulative childhood adversity and adult 
cardiometabolic disease (HR, 1.42, 95% CI, 1.20–1.67; 
OR, 1.36, 95% CI, 1.27–1.46). We know of no evidence 
to suggest that the prevalence of adverse child experi-
ences is declining. Interventions to decrease exposure 
to childhood adversities and mitigate their downstream 
effects are needed.
Social Relationships
In adults, lower social support, less integration into 
social networks, and greater social isolation are as-
sociated with increased risk of morbidity and mortal-
ity.69 Less evidence regarding the cardiovascular risk 
of social relationships is available in adolescents and 
young adults. The Dunedin Multidisciplinary Health 
and Development study showed that social isolation in 
childhood (5–11 years old) based on parent and teacher 
ratings predicted the age 26 summary index of lipids, 
blood pressure, BMI, waist circumference, glycated 
hemoglobin, and maximum oxygen consumption.70 
These effects were independent of childhood family 
SES and overweight. Peer social integration based on 
parental reports of time their sons spent with friends 
from ages 7 to 16 was related to blood pressure and 
BMI when men were in their thirties.71 These relation-
ships were also independent of family SES, childhood 
BMI, and social integration in adulthood. Data from the 
Add Health (National Longitudinal Study of Adolescent 
to Adult Health) study indicated that greater social inte-
gration within peer networks, school, family, and com-
munity during adolescence was associated with lower 
levels of inflammation, blood pressure, BMI, and waist 
circumference in young adulthood.72 Several studies 
have reported that being a victim of bullying was as-
sociated with inflammation, obesity, and psychosocial 
risk factors, in addition to its mental health conse-
quences.73,74 The long-term impact of early social re-
lationships and social relationships in young adulthood 
are an important area for future research.
Sociodemographic Factors
SES has a profound influence on adult CVD risk, 
regardless of whether SES is based on the educa-
tion, the income, or the occupation of the individ-
ual or of family members, or whether these factors 
apply to the neighborhood.10 Many explanations 
of SES and CVD risk association have focused on 
poverty, but it appears that the relationship of SES 
and health is monotonic, such that each increas-
ing level of SES is associated with better health. 
Studies examining the influence of SES across the 
life course have found that low SES in childhood is 
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when statistical adjustments are made for adult 
SES.75,76 Extensive reviews of the literature show 
that lower SES in youth is associated with CVD risk 
factors, including greater exposure to passive and 
active smoking, physical inactivity (eg, more hours 
watching television), obesity, poor sleep health, and 
central adiposity.77–79 In the Add Health study, lower 
SES during adolescence was related to a higher 
Framingham risk score 14  years later.80 Mediation 
analyses showed that educational attainment, fi-
nancial stress, and lack of medical/dental care were 
key pathways to high-risk scores. In the same study, 
lower family income was related to higher systolic 
blood pressure.81
Black and Hispanic youth are more likely to grow 
up in lower SES families and live in lower SES neigh-
borhoods than their White and Asian counterparts. 
Further, although there is evidence from studies that 
Black adults receive less of a health benefit from 
higher SES status than White adults,82,83 only a few 
studies among youth simultaneously consider SES 
and minority status and whether the effects are in-
dependent or synergistic.84 In an analysis of National 
Health Interview Survey data for US children 0 to 18 
years old, lower parental education was associated 
with higher rates of “circulatory conditions” in Black 
and White children and were null or reversed in Asian 
and Hispanic children.85 In the Add Health study, the 
influence of SES on obesity differed by race and gen-
der.86 In several studies of healthy children, low SES 
was related to higher ambulatory blood pressure 
throughout the school day in Black and White chil-
dren, and family income was related to high nighttime 
pressure in Black children only.87,88 Taken together, 
the stage is set by adolescence for a long-lasting ef-
fect of family SES on CVH into adulthood, with more 
adverse among Black and Hispanic young adults, 
with some gender-specific differences.
Neighborhood Factors
Findings from the Add Health study also indicate that 
the prevalence of obesity, as well as high systolic and 
diastolic blood pressures and metabolic syndrome,89 
is lower in young adults who never lived in poor neigh-
borhoods, compared with those who later or consist-
ently lived in poor neighborhoods as adolescents.90,91 
Independent of neighborhood poverty, aspects of 
the neighborhood physical environment, including 
access to healthy foods, walkability, and transporta-
tion have been consistently linked to behaviors such 
as smoking, physical activity, and dietary intake, as 
well as a range of CVD risk factors including BMI, 
hypertension, and DM.92–97 Aspects of the neighbor-
hood social environment including crime, percep-
tions of safety, and reports of neighborhood social 
cohesion have also been associated with a range of 
indices of CVD risk, including smoking, physical in-
activity, dietary quality, insomnia, hypertension, and 
increased BMI.93,98–101
Cohort Effects
Regardless of treatment modality or preventive strat-
egy, trials of any intervention to improve CVH during 
young adulthood will need to understand and navi-
gate the unique socioeconomic characteristics ex-
hibited by 21st century young adults. Young adults 
living in the United States today are less likely than 
previous generations to marry, have children, and 
own their own home.102 The modal living arrangement 
is with their parents (33%), and 1 in 4 young adults 
who live at home are neither working nor in school.102 
Furthermore, though young adults living in the United 
States today are more educated than previous genera-
tions, they have taken on much more debt related to 
their education. Each of these shifts has implications 
for the likelihood and ability of young adults to engage 
in preventive behaviors and pay for health care. These 
contextual factors require consideration for both initi-
ating and sustaining lifestyle modifications,103,104 and, 
if indicated, starting and maintaining adherence to 
antihypertensive, lipid-lowering, or glucose-regulating 
medication.105 These demographic trends are seen 
most often in highly industrial or postindustrial socie-
ties. In other societies and in more rural communities 
in the United States and elsewhere, the phenomenon 
known as “emerging adulthood,” a delayed transition 
to typical adult roles, is less common.12
Technological advances have changed the nature 
of work and leisure time for young adults around the 
world, and in both rural and urban settings. Young 
adults are the most likely age group to own a smart-
phone (92% in 2017), use social media (86%), and be 
dependent on their smartphone for accessing the in-
ternet.106 Thirty-nine percent of young adults report 
they are “constantly online” and 49% report they are 
online “multiple times per day.”107 The beneficial and 
harmful effects of young adults being connected to 
these electronic devices for much of their waking, and 
even their sleeping hours, are unclear. Electronic media 
usage has been associated with insufficient sleep,108 
physical inactivity,109 increased caloric intake,110 and 
elevated BMI111 in young adults, although some stud-
ies find improved nutrition and physical activity among 
young adults who use health-related apps.112
Early young adulthood, between 18 and 21 years 
old, is when individuals transition from pediatric-ori-
ented to adult-oriented healthcare systems in the 
United States.113 Consistent engagement with medi-
cal care is essential for young adults with higher CVD 
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between physician visits is associated with worse hy-
pertension control.114 Yet, many young adults have 
a prolonged gap in care when transferring across 
healthcare systems. A recent national retrospec-
tive study of insured young adults found a gap of 
20.5 months for office visits and 41.7 months for pre-
ventive visits when transitioning from an adolescent 
to adult medical practice.115 Males and young adults 
from lower-income neighborhoods experienced even 
longer gaps in care.115 Young adults also have rel-
atively low rates of preventive care service utiliza-
tion as compared with other age groups. The 2014 
to 2016 Medical Expenditure Panel Surveys, which 
reflect implementation of the Affordable Care Act, 
found that only 23% of young adult men and 42% of 
young adult women received a routine primary care 
examination. Of those who attended any healthcare 
visit in a 3-year period, 86% received blood pressure 
screening, but only 42% received cholesterol screen-
ing. Rates of preventive care were higher in females, 
young adults with higher reported income, and those 
with health insurance.116
CAUSES OF VARIATION IN 
TRAJECTORIES OF CVH
Optimal preventive interventions should consider not 
only who is at greatest risk of adverse CVD outcomes 
based on exposures and individual susceptibility, but 
also when risk develops and when intervention would 
be most beneficial. The schematic in Figure  2 illus-
trates different trajectories of loss of CVH over the 
lifespan in relation to enduring vulnerabilities from the 
influences described above, individual risk behaviors, 
and traditional risk biomarkers. CVD risk factors vary 
in their temporal trajectories across the life course.117,118 
The first parameter in the model is maximal capacity 
for CVH, represented by the y-axis intercept. Various 
genetic, intrauterine, sociodemographic and life event 
factors, operating from conception throughout child-
hood, function as vulnerabilities to impact the maximum 
capacity for CVH.119,120 The second parameter reflects 
the degree of resilience against loss of CVH present 
during young adulthood. The third parameter is the 
slope of the trajectory of loss of CVH; steeper slopes 
represent more rapid loss. Each curve in Figure 2 illus-
trates how these parameters may influence the timing 
and rate of loss of CVH. Optimal is decline after age 
70 to 80 years based on lifelong stably high CVH level 
(green curve in Figure 2). This illustrates the advanta-
geous compression of morbidity until achieving old 
age based on maximal capacity and healthy lifestyle.121 
Most typical is rapid decline from the presence of prior 
moderate CVH during young adulthood; this presages 
reaching suboptimal CVH during late adulthood (yellow 
curve in Figure  2). Unfavorable levels of cardiometa-
bolic and biochemical markers (eg, increased systolic 
blood pressure, increased waist circumference, and 
decline of glomerular filtration rate) are evident at least 
15 to 20 years before CVD diagnosis, indicating that 
risk is partly determined by or during young adult-
hood.122 Those with limited maximal capacity, adverse 
circumstances, and severe or multiple risk will experi-
ence CVD in young adulthood (red curve in Figure 2).
PATHOPHYSIOLOGIC PROGRESSION 
AND RISK PREDICTION: FROM 
SUBCLINICAL CARDIOVASCULAR 
MARKERS TO CVD
Subclinical Atherosclerosis and CVD Risk 
Prediction
Epidemiologic and clinical studies have established 
that atherosclerosis can start during the childhood 
years and progress through young adulthood, leading 
to CHD by middle age.123,124 The PDAY (Pathobiological 
Determinants of Atherosclerosis in Youth) study con-
firmed that advanced atherosclerosis can start in 
late adolescence, with progression of atherosclerotic 
plaque in relation to CVD risk factors occurring in the 
third and fourth decades of life.123 The advanced ath-
erosclerotic lesions seen in some young adults are of 
the type that can rupture and produce acute events.125 
Preliminary analyses, using CARDIA (Coronary Artery 
Risk Development in Young Adults) study data, sup-
port a relationship of these high-grade lesions with 
atherosclerotic events.126 The major traditional risk fac-
tor predictors of advanced atherosclerosis in the PDAY 
study were DM, dyslipidemia, smoking (particularly for 
atherosclerosis in the abdominal aorta), hypertension, 
and obesity (in men). Effects on traditional risk fac-
tors, oxidative stress, and endothelial dysfunction have 
been described as pathways whereby lifestyle risk fac-
tors convert to cardiometabolic risk factors and fur-
ther the progression to atherosclerosis and CVD.127,128 
However, lifestyle risk factors also occur against a 
background of variable inherited and acquired individ-
ual vulnerability to atherosclerosis and cardiovascular 
events28,29 and in a context that offers more or less 
socioenvironmental support.129
Current risk prediction equations for atheroscle-
rotic cardiovascular disease (ASCVD; defined as a 
nonfatal myocardial infarction [heart attack], CHD 
death, or stroke)130,131 use the traditional risk factors of 
age, sex, DM, smoking, total cholesterol, high-density 
lipoprotein cholesterol (HDL-C), systolic blood pres-
sure, antihypertensive therapy, as well as race/eth-
nicity. These equations perform well in non-Hispanic 
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old.132 Insufficient data have been available to develop 
ASCVD risk prediction equations for adults <40 years 
old, or for other racial/ethnic groups.130
A PDAY risk score was developed to predict the 
presence of subclinical atherosclerosis in young adults; 
this score is based on age, sex, HDL-C and non-HDL-C, 
smoking, blood pressure, and glycosylated hemoglo-
bin. The usefulness of this score was confirmed in both 
the CARDIA study133 and the Young Finns Study.134 A 
critical finding was that the PDAY score calculated in ad-
olescents (Young Finns Study) or at age 18 to 30 years(-
CARDIA study) was more predictive than risk factors 
measured later in adulthood for higher carotid intima 
media thickness or presence/intensity of coronary ar-
tery calcium measured 15 to 25  years later. Between 
40% and 60% of those with a high PDAY score will have 
advanced atherosclerosis. These observations suggest 
that atherosclerosis present in young adulthood is the 
result of chronic risk exposure over a lifetime; early pre-
vention efforts can reduce the atherosclerotic burden 
in middle age.135,136 Longitudinal studies with childhood 
and adult measures of subclinical atherosclerosis con-
sistently show independent relationships of youth risk 
factors to adult outcomes.137
CVD Risk Based on Hypertension and DM
There is a high prevalence of uncontrolled hypertension 
among young adults.105,138–141 Up to 38% of hyperten-
sion goes undetected before age 40.142 Hypertension 
in young adulthood has been associated with ad-
verse cardiovascular outcomes later in life, with many 
of these events occurring before age 50  years.143–145 
Multiple studies have demonstrated that Black young 
adult men and women have an earlier onset and more 
severe hypertension compared with young adult White 
men and women.141,146 Analysis of 24-hour ambula-
tory blood pressure data found a higher mean 24-hour 
blood pressure, higher prevalence of nocturnal hy-
pertension, and higher rates of masked hypertension 
among young Black men and women compared with 
White men and women of similar age.141,147 Historical 
cohort studies also have found more severe baseline 
hypertension (>160/95  mm  Hg) among Black young 
adults and its association with higher rates of hyper-
tension-related mortality.141
More concerning is that the severity of hyperten-
sion among Black young adults is often underesti-
mated using blood pressure measurements taken in 
a clinic.141,147 Analyses of blood pressure trajectories 
highlight the emergence of age, gender, and racial/
ethnic hypertension disparities beginning at least as 
early as 8 years old.146 Using 2007 to 2012 data from 
the National Health and Nutrition Examination Survey, 
there were earlier transitions from ideal blood pressure 
(<120/80  mm  Hg) to prehypertension, and ultimately 
sustained hypertension among boys (compared with 
girls) and Black compared with White youth.146 With 
the updated 2017 American College of Cardiology 
and American Heart Association high blood pressure 
guidelines defining hypertension as a blood pressure 
≥130/80 mm Hg, there is now a greater prevalence of 
elevated blood pressure (120–129/<80  mm  Hg, pre-
viously “prehypertension”) and hypertension among 
young adults.148 Disparities in the incidence and sever-
ity of hypertension also contribute to similar disparities 
noted in the prevalence of heart failure among young 
adults.149 In the CARDIA study, 20-year follow-up of 
18- to 30-year-olds found higher rates of incident heart 
failure among Black males and females compared with 
White men and women. Of note, Black young adults in 
the United States carry a disproportionate burden of 
many psychosocial contributors to poor CVH including 
poverty and stress noted above. Thus, the accrual of 
CVD risk for Black young adults can be profound.
The prevalence of DM in adolescents and young 
adults is increasing.150,151 Both type 1 and type 2 DM 
have been related to early vascular dysfunction, and 
share risk factors similar to those for CVD including 
hypertension, dyslipidemia, microalbuminuria, inflam-
mation, and hyperglycemia.152 However, young-onset 
type 2 DM appears to be associated with manifesta-
tion of the vascular abnormalities earlier and at lower 
glycosylated hemoglobin levels, despite shorter dura-
tion of diagnosed DM.153,154
PRIMORDIAL AND PRIMARY 
PREVENTIVE INTERVENTIONS IN 
YOUNG ADULTS
Two main intervention strategies are available to curb 
longitudinal loss of CVH (Figure 4). Primordial preven-
tion intervenes to deter the development of risk factors 
by focusing on the outer level of influences (Figure 1).155 
Examples targeting the entire population include media 
health education campaigns and policy interventions 
(eg, Clean Indoor Air Act, sugar-sweetened bever-
age tax, fruit and vegetable subsidies, and zoning 
ordinances to make neighborhoods more walkable). 
Primary prevention treats individuals who already have 
risk factors to reduce their odds or slow their trajec-
tory of progression toward CVD events. This is typically 
focused on the innermost level of individual influences 
(Figure 1).
Role of Healthcare Engagement by Young 
Adults for CVH Promotion and Disease 
Prevention
For primary prevention to reach young adults with 
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care must be overcome. Policies are critically 
needed to offer young adults continuous, afford-
able health insurance and consistent care access 
without racial and socioeconomic disparities. At a 
healthcare systems level, it is important that primary 
and specialty care practices recognize the transi-
tions that occur throughout young adulthood. To 
maintain young adults’ continued engagement, tra-
ditional outpatient clinics may need to accommo-
date their preferences for convenient, integrated, 
and flexible care, by offering services during evening 
or weekend hours or via telemedicine.156 Similarly, 
young adults may prefer using technology to sched-
ule health appointments, access health records, 
and monitor engagement in health-related behav-
iors by using their own mobile/wearable devices. By 
incorporating data from mobile devices and wear-
able devices, the healthcare provider can potentially 
partner with patients to provide tailored assess-
ments and behavior-change advice.157,158 Although 
integration of patients’ digital data into the elec-
tronic health record to support connected care re-
mains in its infancy, such infrastructure has already 
become a reality at some institutions.159 Expansion 
of training programs with a young adult focus, such 
as joint pediatric and adult medicine training, can in-
crease developmentally tailored programs for young 
adults.160
Community-Based CVH Promotion and 
Disease Prevention
Given low overall rates of engagement with traditional 
medical settings, novel programs may be needed 
to promote healthy behaviors among young adults. 
Because young adults are highly represented in the 
workforce, health promotion programs delivered in 
occupational settings may be particularly beneficial 
to promote heart-healthy behaviors.161 Also, link-
ing preventive health care to concern for the envi-
ronment (eg, lower environmental impact of wholly 
plant-based or reduced animal protein diets, walk-
ing, or biking) and to other motivational factors may 
appeal to young adult values. Similarly, social media 
may be harnessed to promote health knowledge and 
motivation among difficult-to-reach or disengaged 
young adults.162 It is important to respect young 
adults’ need for privacy on social media and provide 
resources for how to find and identify credible health 
information.163 Provision of high-quality, coordinated 
care for young adults will require improved commu-
nication across healthcare systems and providers 
who may work in student health, retail-based, and 
urgent-care clinics. By incorporating these care de-
livery entities outside of traditional health settings, 
coordinated care may be able to catch young adults 
where they are receiving care.
Figure 4. Risk factor intervention.
Two main intervention approaches to preventing the development of (primordial prevention) or treating already developed cardiovascular 
risk factors (primary prevention). Either intervention approach can deploy behavioral-socioenvironmental or pharmacologic treatment 
modalities. The intervention targets depicted (in hexagons) are the established cardiovascular risk factors included in the American 
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Population-Wide Health Interventions
Population-wide interventions have the potential to 
reach those of low SES, smokers, and consumers of 
low-cost, unhealthy diets who are often not linked to 
medical care. Population-based interventions may be 
especially relevant to young adults, who may be dis-
engaged from the formal healthcare sector and may 
choose to prioritize immediate concerns over long-
term health risks. Some of the best-supported popula-
tion-wide interventions involve laws and policies.
Two particularly impactful tobacco control policies 
legislated at the state or municipal level have been 
tobacco product taxation, passed on to the con-
sumers at the point of purchase, and tobacco bans, 
which outlaw smoking in workplaces, public tran-
sit, restaurants, and bars. The National Longitudinal 
Survey of Youth found that a $1 increase in to-
bacco excise taxes lowers the odds of daily heavy 
smoking in young adults (1 or more packs per day) 
by 17.9%.164 Young adults living in cities with com-
prehensive smoking bans were 21.1% less likely to 
smoke. Electronic cigarettes share the same addic-
tive properties as traditional tobacco products, but 
have only recently become popular among adoles-
cents and young adults. The health effects of elec-
tronic cigarettes have not been well-described, but 
early evidence shows that young adults who start 
as never-smokers and start using electronic ciga-
rettes are 3.6 times more likely to become regular 
tobacco smokers than those who avoid electronic 
cigarettes.165 This suggests that stronger electronic 
cigarette regulation in young adults could limit the 
population of young adult and longer-term tobacco 
smokers.
Recently, population-wide interventions have 
been applied to the risk factors of poor-quality diet 
and physical inactivity with the rationale that power-
ful environmental contexts make individual behavior 
changes difficult to sustain. Examples include food 
sources dominated by packaged, processed, and 
high-calorie foods with low nutritional value and built 
and workplace environments that encourage seden-
tary habits. New York City 2006 government regu-
lation of trans-fatty acid use in restaurant cooking 
led to a 62% reduction in mean serum trans fatty 
acid levels in adults between 2004 and 2014.166 In 
the United Kingdom, food companies were encour-
aged by the government to make voluntary agree-
ments to lower sodium content in packaged foods 
starting in 2006. Young adults in the United Kingdom 
(16–34 years old) had the highest sodium consump-
tion at baseline of any age group (6.6 g/d in 2003) 
and experienced a 9.5% decrease in daily sodium 
intake by 2007.167 An excise tax on sugar-sweetened 
beverages introduced in Berkeley, California, led to 
reduced consumption of sugar-sweetened beverages 
and increased consumption of untaxed beverages 
(eg, water).168,169 Not all public health interventions 
need be punitive. For example, the US Supplemental 
Nutrition Assistance Program, introducing incentive 
subsidies to encourage consumption of fruits and 
vegetables combined with a sugar-sweetened bev-
erage ban, could lead to substantial lifetime health 
gains and be cost-effective.170
Individual Behavioral Interventions
Systematic evidence reviews of behavioral interven-
tions for the general adult population suggest their ben-
efit on intermediate CVD risk factors, diet, and exercise 
behaviors,171 as well as tobacco cessation.172 Less evi-
dence exists for young adults specifically. Traditionally, 
young adults have been underrepresented in behavio-
ral intervention trials. For example, in a pooled analysis 
of lifestyle interventions for weight loss, young adults 
represented <10% of the sample, attended 25% fewer 
sessions than older adults, and were less likely to be 
retained at follow-up.173,174
The EARLY (Early Adult Reduction of Weight through 
Lifestyle Intervention) trial, a consortium of 7 random-
ized controlled trials funded by the National Institutes of 
Health, sought to address this gap by enrolling only in-
dividuals 18 to 35 years old in 2-year behavioral weight 
control interventions.175 The EARLY trial enrolled over 
4000 young adults, and had an average retention of 
83% at 2 years across all 7 studies, demonstrating that 
young adults are interested in and can be successfully 
retained in long-term behavioral trials designed spe-
cifically for them.175–181 Retention was variable across 
populations and follow-up methods; whereas 97% of 
weights were obtained using electronic medical re-
cords, fewer (68%) were obtained when directly mea-
sured in the clinic. Results across EARLY studies were 
variable, with some studies showing significant weight 
loss178 or weight gain prevention at 2 years181 and oth-
ers showing only short-term weight loss or effects on 
secondary outcomes.175,177,180
In an effort to appeal to young adults, each of the 
EARLY studies used digital tools, either alone or in 
combination with face-to-face methods. Systematic 
reviews and meta-analyses provide evidence that 
using digital health tools can produce positive short-
term effects on smoking cessation182 and weight 
control.183 Digital and hybrid treatments that com-
bine digital with phone or face-to-face care can vary 
significantly with respect to content and intensity.184 
Generally, interventions with greater dose, tailoring, 
and inclusion of a human coach or counselor have 
been more effective. The outcomes across the 7 
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Moving forward, behavioral research should focus 
on optimizing interventions such that more potent, ef-
ficient, and scalable interventions are developed and 
tested. The multiphase optimization strategy, an engi-
neering-inspired framework, encourages experimental 
approaches to the selection and configuration of in-
tervention components. The multiphase optimization 
strategy offers a suite of research designs that test how 
to optimize interventions so that they achieve the max-
imum effect possible given resource constraints.185,186 
Adaptive interventions (those that deliver sequential 
treatments or intensities based on progress) address 
heterogeneity of outcomes in behavioral interventions 
and may be particularly important for young adults 
who face different life events and circumstances that 
pose challenges for behavior change.185,187 Just-in-
time-adaptive interventions capitalize on real-time data 
from young adults’ ubiquitous mobile technologies to 
adapt the timing and content of interventions day to 
day and even moment to moment.188 Emerging ge-
nomic, metabolomic, and microbiome data may also 
help to understand the heterogeneity of behavioral 
treatment outcomes and expand the set of predictors 
and treatment-matching variables available to person-
alize intervention selection.
Individual Pharmacologic Interventions
Current clinical practice guidelines for the primary pre-
vention of ASCVD have been based on evidence from 
cardiovascular outcomes trials that have enrolled in-
dividuals ≥40 years old for the end points of ASCVD 
events, heart failure, cardiovascular or total mortality, or 
atherosclerosis progression.131,189 Few trials targeting 
the exclusively primary prevention population included 
participants who were <50  years old: Ages ranged 
from a mean of 57 to 66 years old.190–193 An ongoing 
10-year primary prevention statin trial is enrolling men 
35 to 50 years old and women 45 to 59 years old.194 
Although randomized trial data suggest that greater re-
ductions in the relative risk of ASCVD occurred when 
statins were used in lower-risk (eg, younger) individu-
als,195 the absolute risk of ASCVD events is low be-
fore age 50 years, especially in women, who have a 
lower absolute risk of premature CHD.196,197 Clinical 
trials with cardiovascular outcomes as end points in 
younger adults would require either a very large sam-
ple size and duration >5  years, identification of very 
effective interventions with large reductions in relative 
risk of ASCVD, or more precise identification of the 
most susceptible populations with the highest risk of 
nearer-term ASCVD events.
On the other hand, trials focused on preventing 
the development or progression of atherosclerosis, 
early predictors of heart failure, or progression of hy-
pertension are feasible in younger adults. Populations 
at higher risk in young adulthood include those with 
hypertension, early-onset DM (type 1 or type 2), fa-
milial hypercholesterolemia, or multiple risk factors 
associated with obesity. It could be expected that 
prevention of atherosclerosis or stabilization of early 
atherosclerotic plaque would largely prevent the sub-
sequent manifestation of clinical ASCVD later in life. 
Because apolipoprotein-B containing lipoproteins 
appear to play a key causal role in the development 
and progression of atherosclerosis, interventions to 
lower LDL-C or non-HDL-C may hold promise for 
influencing atherosclerosis progression.198 Clinical 
trials of high-intensity statins and proprotein conver-
tase subtilisin-like/kexin type 9 monoclonal antibod-
ies have shown that atherosclerotic plaque volume 
can be reduced in middle-aged adults with more ad-
vanced stages of atherosclerosis.199 However, animal 
data suggest that intensive LDL-C lowering in younger 
high-risk adults may have an even greater impact 
on plaque regression and the potential to normalize 
arterial function.198,200 Validation of this approach in 
cardiovascular outcomes trials would also lay the 
groundwork for an early-intervention approach to 
lifetime ASCVD prevention. Notably, proprotein con-
vertase subtilisin-like/kexin type 9 inhibition provides 
a promising target for such interventions because it 
is the key regulator of LDL-C receptor expression, 
though available drugs are costly.201
Some evidence suggests regression of early ath-
erosclerosis, reduction in arterial stiffness, and nor-
malization of endothelial function could also prevent or 
delay the later development of hypertension.202–205 The 
urgency to reduce premature heart failure, stroke, and 
chronic kidney disease among young adults is increas-
ingly recognized; multiple young adult hypertension 
trials are in progress.206–208 Several statin trials have 
found reductions in blood pressure and hypertension 
incidence in statin-treated patients.209 Proprotein con-
vertase subtilisin-like/kexin type 9 inhibitors have also 
recently been shown to improve endothelial function 
in proportion to the magnitude of LDL-C lowering.210 
Similar approaches have been taken to prevent pro-
gression of hypertension or improve subclinical mark-
ers of future heart failure.211 The new blood pressure 
guidelines present new opportunities to discuss and 
launch trials to improve blood pressure management 
in young adults, including studies of interventions to 
improve treatment adherence that have the poten-
tial to prevent millions of CVD events.212 In individuals 
with DM, ongoing trials seem reassuring with respect 
to cardiovascular safety of newer agents such as so-
dium-glucose cotransporter-2 inhibitors and gluca-
gon-like peptide-1 receptor agonists. These agents 
may prove to be significant adjunct therapies in the 
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Imaging data, coupled with risk factor, genetic, and 
metabolomics characteristics, could potentially be used 
to characterize the phenotypes of the young adults 
most responsive to intensive LDL-C-lowering therapies, 
antihypertensive therapy, or for planning future definitive 
trials with cardiovascular outcomes,198 particularly if the 
markers have strong associations with future events. 
Imaging data are available to understand the factors 
influencing progression of atherosclerosis throughout 
the lifespan. No data are available regarding the impact 
of earlier treatment of atherosclerosis. Intimal medial 
thickness has been assessed in European ancestry 
children and younger adults, with limited long-term fol-
low-up or treatment response data. Coronary artery 
calcification measured by computed tomography is 
associated with the presence of advanced plaque and 
increased risk of cardiovascular events, but cannot be 
used to assess response to therapy.213–215 Moreover, 
coronary artery calcium occurs later in the course of 
atherosclerosis progression and may be absent in high-
risk younger adults with a substantial burden of noncal-
cified plaque.197 Computed angiographic tomography 
has emerged as the preferred choice for evaluating and 
characterizing composition of coronary plaque, and 
strongly predicts ASCVD events and response to ther-
apy.216–223 The latest generation of scanners has less 
radiation exposure than a mammogram. Newer nonin-
vasive technologies such as positron emission tomog-
raphy can assess inflammation and are promising for 
understanding earlier stages of plaque development.197 
A similar process could be followed to examine cardiac 
function markers, as assessed by echocardiography 
and magnetic resonance imaging, in relation to future 
heart failure risk.224,225
RESEARCH OPPORTUNITIES
Given the demonstrated necessity of improving the 
CVH of young adults, prioritizing research areas will 
be critical. Future research should focus on identi-
fying effective strategies that improve control of risk 
biomarkers via evidence-based strategies and pro-
mote healthy lifestyle behaviors. Emphasis should be 
placed on young adults who experience health dis-
parities and are at highest risk for early cardiovascular 
events, as they often experience inadequate educa-
tion, lower SES, exposure to psychosocial stress, and 
identification as part of a racial/ethnic minority popu-
lation.226 Given the unique characteristics of today’s 
contemporary young adults, future research should 
integrate cutting-edge digital approaches into all as-
pects of study design. This could include leveraging 
innovative assessment methods that easily integrate 
patient self-entry of data, transmit home blood pres-
sure measurements, and automatically capture dense 
digital data from wearable devices (eg, physical activ-
ity sensors, sleep trackers, continuous glucose moni-
tors). The use of population management tools to 
capitalize on the wealth of information available from 
electronic health records has the potential to improve 
reach and recruitment of high-risk young adults. Next 
steps in leveraging technology include exploring how 
digital tools can extend traditional retention strate-
gies (eg, use of reminders, financial incentives) and 
can inform emerging strategies that build participant 
trust.227–229
Here, we prioritize 3 critical research areas: primor-
dial prevention, primary prevention, and implementation 
science. First, research on primordial prevention—the 
improvement in population-based metrics such as to-
bacco use, obesity prevalence, dietary choices, physi-
cal activity, and sleep habits—could identify new ways 
to lower the prevalence of cardiovascular risk factors 
in the population. Tobacco control provides many ex-
amples of strategies to lower population risk exposure, 
as does the decades-long success in lowering choles-
terol levels in the population via awareness of excess 
saturated fat intake and elimination of trans fats from 
the food chain. Public health intervention strategies to 
curb the obesity epidemic and improve engagement of 
young adults with preventive health care are promising 
opportunities.
Second, clinical trials of promising primary pre-
vention strategies could identify new approaches to 
prevention of CVD in young adults, especially those 
with significant behavioral risk factors, genetic fac-
tors, and presence of subclinical cardiovascular 
dysfunction or vascular abnormalities. For example, 
these trials could target women with high-risk preg-
nancies or individuals with multiple risk behaviors or 
psychosocial stressors, such as exposure to child-
hood adversity. Potential outcomes include improve-
ments in end-organ injury (eg, slowed atherosclerosis 
progression, improved vascular function, improved 
cardiac function, prevention of incident hypertension, 
prevention of renal injury) as well as reduction of early 
ASCVD events.
Third, implementation science studies could inform 
approaches to increase the uptake of effective primary 
prevention and risk factor control strategies for young 
adults with established risks (hypertension, dyslipid-
emia, DM) for whom evidence-based treatment guide-
lines exist. Gaps exist in recognition of risk, initiation 
of treatment, and adherence to treatment, some of 
which may be created by disparities based on race, 
ethnicity, gender, education, and lack of health insur-
ance coverage. In young adults, an important question 
is whether it may be more useful to set implementation 
trials in community settings (eg, workplaces, pharma-
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SUMMARY
This review summarizes discussions from a 2-day 
workshop in Bethesda, Maryland, in September 2017 
to identify research challenges and opportunities re-
lated to the CVH of young adults (18–39  years old). 
There are substantial observational data documenting 
lack of progress in CVD prevention in this group, as 
evidenced by the significant prevalence of risk factors 
attributable to multiple contributors. Significant knowl-
edge gaps remain concerning the ability of public 
health agencies and/or healthcare delivery systems to 
act on this information. Future research opportunities 
include understanding the influence of the substantial 
change in the lifestyles of young adults over the past 
few decades, addressing the lack of engagement of 
young adults in the healthcare system, developing in-
terventions to mitigate health disparities, and address-
ing the paucity of clinical trials for both behavioral and 
pharmacologic interventions. Given strong evidence 
that the origins of chronic CVD begin at a young age, 
the greatest opportunity to eradicate heart disease in 
the future is likely primordial and primary prevention 
beginning in young adulthood, if not earlier.
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